

Number 866 • June 2020

Product supply shortage addressed for *Alberta Human Services Drug* Benefit Supplement (HSDBS)

Alberta Blue Cross has been advised by Odan Laboratories Ltd. that the shortage for Ferodan 75 mg/ml Infant Drops (NPN 02237385) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **July 8, 2020**.

FERROUS SULFATE

75 MG/ML DROPS			
00002237385	FERODAN INFANT	ODN	\$ 0.1432
00000762954	FER-IN-SOL	OLM	\$ 0.2558

Product supply shortage addressed for Alberta Drug Benefit List (ADBL)

Alberta Blue Cross has been advised by Auro Pharma Inc., Sivem Pharmaceuticals ULC, and Pharmascience Inc. that the shortages for Auro-Losartan HCT 100 mg/25 mg Tablet (DIN 02423669), Losartan/HCT 100 mg/25 mg Tablet (DIN 02388987), pms-Losartan-HCTZ 100 mg/25 mg Tablet (DIN 02392240), respectively have been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **July 9, 2020**.

LOSARTAN POTASSIUM/ HYDROCHLOROTHIAZIDE

100 MG / 25 MG TABLET

00002423669	AURO-LOSARTAN HCT	AUR	\$ 0.3146
00002408252	JAMP-LOSARTAN HCTZ	JPC	\$ 0.3146
00002388987	LOSARTAN/HCT	SIV	\$ 0.3146
00002427664	LOSARTAN/HCTZ	SNS	\$ 0.3146
00002389673	MINT-LOSARTAN/HCTZ DS	MPI	\$ 0.3146
00002392240	PMS-LOSARTAN-HCTZ	PMS	\$ 0.3146
00002313383	SANDOZ LOSARTAN HCT DS	SDZ	\$ 0.3146
00002428547	SEPTA-LOSARTAN HCTZ	SEP	\$ 0.3146
00002377152	TEVA-LOSARTAN/HCTZ	TEV	\$ 0.3146
00002241007	HYZAAR DS	MFC	\$ 1.4140

Product supply shortage addressed for Alberta Drug Benefit List (ADBL)

Alberta Blue Cross has been advised by Auro Pharma Inc., Sivem Pharmaceuticals ULC, and Pharmascience Inc. that the shortages for Auro-Losartan HCT 50 mg/12.5 mg Tablet (DIN 02423642), Losartan/HCT 50 mg/12.5 mg Tablet (DIN 02388960), pms-Losartan-HCTZ 50 mg/12.5 mg Tablet (DIN 02392224), respectively have been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **July 13, 2020**.

LOSARTAN POTASSIUM/ HYDROCHLOROTHIAZIDE

50 MG / 12.5 MG TABLET

00002423642	AURO-LOSARTAN HCT	AUR	\$ 0.3146
00002408244	JAMP-LOSARTAN HCTZ	JPC	\$ 0.3146
00002388960	LOSARTAN/HCT	SIV	\$ 0.3146
00002427648	LOSARTAN/HCTZ	SNS	\$ 0.3146
00002389657	MINT-LOSARTAN/HCTZ DS	MPI	\$ 0.3146
00002392224	PMS-LOSARTAN-HCTZ	PMS	\$ 0.3146
00002313375	SANDOZ LOSARTAN HCT DS	SDZ	\$ 0.3146
00002428539	SEPTA-LOSARTAN HCTZ	SEP	\$ 0.3146
00002358263	TEVA-LOSARTAN/HCTZ	TEV	\$ 0.3146
00002230047	HYZAAR DS	MFC	\$ 1.4140

Alberta Blue Cross has been advised by Omega Laboratories Limited that the shortage for Octreotide Acetate Omega 200 mcg/ml Injection (DIN 02248642) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **July 13, 2020**.

OCTREOTIDE ACETATE

200 MCG / ML INJECTION			
00002248642	OCTREOTIDE ACETATE OMEGA	OMG	\$ 6.3420
00002049392	SANDOSTATIN	NOV	\$ 18.6861

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free) **FAX 780-498-8406** (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims. **Visit** ab.bluecross.ca/providers/pharmacy-home.php



